Cognitive Function After Radiation Therapy for Brain Tumours
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Primary Brain Tumor
- Sponsor
- University of Aarhus
- Enrollment
- 104
- Locations
- 1
- Primary Endpoint
- Memory impairment (as assessed by the HVLT-r)
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This study will assess cognitive function in adult patients with a primary brain tumour treated with surgical resection with or without radiation therapy (RT). All types of brain tumours apart from glioblastoma will be included
Detailed Description
RT to brain tumours causes cognitive dysfunction. The extent of RT induced changes in cognitive function and radio-sensitivity of the brain is unknown. RT with protons instead of photons spares the healthy brain tissue more and is believed to reduce the risk of cognitive dysfunction. There is modest knowledge on which parts of the brain the investigators need to spare, to prevent cognitive dysfunction. The study is a cross sectional study assessing cognitive function in patients with brain tumours previously treated with RT compared to a similar non irradiated group. 104 patients with specified brain tumours from Aarhus University Hospital treated in the period 2006-2016 will be included. The patients will do patient reported outcome (PRO) and undergo neuropsychological assessment with standardized tests: They will do this prior to RT treatment and ½, 1, 3 and 5 years afterwards. The PRO's included measures on quality of life, fatigue, sleep, depression, anxiety, and socio demografica. The standardized tests are: Trail making Test (TMT); Hopkins Verbal Learning Test (HVLT); Controlled Oral Word Association Test (COWAT) - Animals and S; Coding and Digit Span from WAIS-IV; Paced Auditory Serial Addition Test (PASAT). The correlation between cognitive scores and RT dose-volume parameters to specific areas in the brain will be tested.
Investigators
Morten Høyer
Professor
University of Aarhus
Eligibility Criteria
Inclusion Criteria
- •The participant must be 18 years or older and Danish speaking.
- •Performance status 0-2
- •Capable of cooperating on testing
- •Diagnosed with one of the following diagnoses according to WHO 2016 classification 16 and been treated between 2006 and 2016
- •ZM93803 glioma (exclusive glioblastoma)
- •ZM9401/3 anaplastic astrocytoma, IDH mutant
- •ZM9400/3 diffuse astrocytoma, IDH-mutant
- •ZM9411/3 gemistocytisk astrocytoma, IDH mutant
- •ZM9400/3 diffuse astrocytoma, NOS
- •ZM9451/3 anaplastic oligodendroglioma, IDH mutant and 1p/19q-co deleted
Exclusion Criteria
- •Performance status 3-4 Progression after radiation therapy
Outcomes
Primary Outcomes
Memory impairment (as assessed by the HVLT-r)
Time Frame: 1-10 years after treatment
To examine the correlation between memory impairment (assessed by HVLT-r) and mean dose to the hippocampus.
Neurocognitive function
Time Frame: 1-10 years after treatment
Examine correlations cognitive decline and subvolumes of the brain. Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP). Measures on cognitive test is time in seconds or number of "corrects".
Secondary Outcomes
- Global Health - Quality of life(1-10 years after treatment)
- Patients assessment of own cognitive function(1-10 years after treatment)
- Sleep quality(1-10 years after treatment)
- Depression/Anxiety(1-10 years after treatment)
- Fatigue(1-10 years after treatment)